Diana V. Do, MD, discussed the balance between efficacy and risk when it comes to geographic atrophy medications at Retina 2024. She emphasized the importance of considering efficacy, safety, cost, and treatment burden when selecting a medication for patients. Two FDA-approved therapies for geographic atrophy, Syfovre and Izervay, were discussed, and it was noted that rare but serious side effects have been reported. Do highlighted the importance of reporting any rare side effects to both the company and the American Society of Retina Specialists, and stressed the need to analyze the benefit-risk ratio before prescribing or recommending these drugs to patients.
Source link
Clinicians must weigh risks of geographic atrophy medications
